Drugmakers Expect More Feedback, 6 Percent Fee Increase Under PDUFA V

Drugmakers can expect to see greatly enhanced review communications from the FDA, including mid-cycle updates, under the industry-FDA agreement for the fifth iteration of the Prescription Drug User Fee Act (PDUFA).
Drug Industry Daily